Placement Completed
Freenome placement
US$240m raised
Announced 5 Dec 2025 · NASDAQ: FRNM · US$10.00 cash per share
Advisers
Lead managers
- Legal adviser
- Placement agent
- Jefferies
(co)Leerink Partners (co)
- Issuer
- Freenome
- Issuer based in
- United States
- Completed
- 24 Jul 2026
- Sector
- Diagnostics
- Tags
- Diagnostics, Oncology, Life Sciences
Similar deals
- Alamar Biosciences IPO Apr 2026 · US$191m · Life Sciences
- Avenzo Therapeutics placement Jun 2026 · US$215m · Biotech
- Sensei Biotherapeutics placement Feb 2026 · US$200m · Biotech
- Aktis Oncology IPO Jan 2026 · US$318m · Biotech
- Obsidian Therapeutics placement Apr 2026 · US$350m · Biotech
Sources
- 17 Jun 2026 Final IPO prospectus (424B4), Freenome Holdings, Inc. sec.gov
- 23 Jul 2026 Goodwin Advised Freenome in Business Combination With Perceptive Capital Solutions Corp. and $310 Million Financing goodwinlaw.com
- 24 Jul 2026 Press release (EX-99.2, exhibit), Freenome Debuts as a Publicly Traded Company sec.gov

